

Fig. 5. Cytotoxic effect of PSI treatment on SH-SY5Y cells. The cells were treated with or without PSI for 24 h. (A) Phase-contrast microscopy; (B) nuclear staining with Hoechst 33342, (C) quantitative measurement of apoptotic and necrotic cells. Apoptotic cells were assessed from condensed nuclei stained with Hoechst 33342. The column and the bar represent the mean and SD of the number of dead cells, respectively, expressed as the percentage of the total. The open and the filled columns represent necrotic and apoptotic dead cells, respectively. \* $p < 0.05$  from control.




Fig. 6. Acrolein-modified protein in rotenone-treated SH-SY5Y cells. The cells were treated with 5  $\mu$ M rotenone (+) or without (-) for 3 d and the subcellular fractions were prepared. I: cytoplasm; II: P<sub>1</sub> fraction (nuclei, plasma membrane); III: P<sub>2</sub> fraction (mitochondria). Proteins were immunoblotted with an antibody against acrolein-modified protein. In the P<sub>1</sub> fraction, aggregated acrolein-modified proteins were detected at the top of the gel.

enzymatic activity of proteasome (post-glutamyl peptidase-like activity) measured with a synthetic fluorescent substrate, carbobenzoxy-L-leucyl-L-leucyl-L-glutamic acid  $\alpha$ -(4-methylcoumaryl-7-amide) [Z-Leu-Leu-Glu-MCA],

reduced in a time- and dose-dependent way and virtually was not detected after 4 d treatment with rotenone, as shown in Table 1.

The lysate of rotenone-treated cells was immunoprecipitated with antibody against the

Table 1  
Effects of Rotenone Treatment on Proteasome Activities in SH-SY5Y Cells

Rotenone (25 nM)	ATP (2 mM)	Proteasome activity in SH-SY5Y cells treated with rotenone (pmole/min/μg protein)	
		After 6 h	After 96 h
Control	-	0.89 ± 0.11 <sup>a</sup>	5.19 ± 0.47
	+	1.76 ± 0.02	8.21 ± 0.11
Sample	-	0.97 ± 0.02	0.96 ± 0.04
	+	2.25 ± 0.02	1.80 ± 0.13

Cytoplasmic fraction was prepared from the cells treated with 25 nM rotenone. Postglutamyl peptidase-like proteasome activity was measured fluorometrically using Z-Leu-Leu-Glu-MCA as a substrate with or without the addition of ATP (2 mM).

<sup>a</sup> Mean ± SD of four experiments.




Fig. 7. Modification of the 20S  $\beta$ -subunit of proteasome with acrolein after treatment with rotenone. The cells were treated with 25  $\mu$ M rotenone (rotenone-treated) or without (control) for 4 d, lysed, and precipitated with antibody against the 20S  $\beta$ -subunit. The immunoprecipitant was subjected to Western blot analysis with antibody against acrolein-modified protein. The 20S  $\beta$ -subunit in the precipitant was visualized with anti-20S  $\beta$ -antibody (20S  $\beta$ ). A filled arrow shows that 20S  $\beta$  was modified with acrolein.

20S  $\beta$ -subunit and the subunit protein was modified by acrolein, as shown by Western blot analysis with anti-acrolein antibody (Fig. 7). Acrolein-modified proteins other than the 20S  $\beta$ -subunit were also detected in the immunoprecipitant, suggesting that the oxidized proteins might serve as substrates of 20S proteasome and the aggregated ones might inhibit the activity. However, it requires further

studies to clarify whether the acrolein-modified protein can directly inhibit the proteasome activity, as in the case of 4-HNE proteins (32).

### Apoptotic Signal Activated by ROS-RNS

Both SIN-1 and NO induce apoptosis in SH-SY5Y cells by opening a megachannel called mitochondrial permeability transition pore (mPTP) with a decline in mitochondrial membrane potential ( $\Delta\Psi_m$ ), as shown in Fig. 8. Opening of mPTP induces matrix swelling and physical disruption of the outer membrane in mitochondria and the release of  $Ca^{2+}$ , cytochrome-*c*, and apoptosis-inducing factors into cytoplasm. The mPTP is a protein complex composed of a voltage-dependent anion channel and other components located at the contact site between the mitochondrial outer membrane and inner membrane, and the opening is regulated by Bcl-2 in the outer membrane and the adenine nucleotide translocator in the inner membrane (2). Bcl-2 family proteins regulate cell death induced by oxidative stress and other stimuli, either in a preventing way (Bcl-2 and Bcl-xL) or a promoting way (Bax, Bad, and Bid). The antiapoptotic function of Bcl-2 is mediated by maintaining




Fig. 8. Reduction in  $\Delta\Psi_m$  by SIN-1 treatment and the effect of neuroprotective rasagiline. SH-SY5Y cells were treated with SIN-1 (250  $\mu\text{M}$ ) for 1 h, with or without pretreatment with 0.1  $\mu\text{M}$  rasagiline, and stained with 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-benzimidazolylcarbocyanine iodide (JC-1). The level of  $\Delta\Psi_m$  was determined from red fluorescence, indicating JC-1 aggregates in intact mitochondria.

mitochondria-cytosolic coupling of oxidative phosphorylation, preventing the opening of mPTP and functioning as an antioxidant, either directly or by upregulating other ROS scavengers.

The opening of the mPTP by ONOO<sup>-</sup> has been considered to be the result of the nitration of tyrosine residues in the mPTP to release cytochrome-*c* (33) or of cytochrome-*c* itself (34), to the oxidative crosslinking of thiol groups with protein amalgamation and pore formation, or to the lipid peroxidation to generate 4-HE and acrolein with the potential to induce permeability transition. As another mechanism, ONOO<sup>-</sup> might modify the Bcl-2 family and change the localization and function, as in the case of Bax (35). The opening of the mPTP activates caspase-3, the executor of apoptosis, as shown in Fig. 9 A, induces translocation of glyceraldehydes-3-phosphate dehydrogenase (GPDH) into nuclei, and, finally, fragmentation of nuclear DNA.

Aside from apoptotic signaling in mitochondria, several different protein kinases, including p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK), were reported to be involved in apoptosis induced by ROS-RNS (36-38). As shown in Fig. 9 B, an inhibitor of p38 MAPK, SB202190, prevented the activation of caspase-3 and apoptosis

induced by ONOO<sup>-</sup>, suggesting that p38 MAPK might be also involved in apoptosis induced by ONOO<sup>-</sup>. In addition, ONOO<sup>-</sup> activated extracellular signal-regulated kinase (ERK) kinase (MEK1), the phosphorylation of which was inhibited by PD98059, a selective inhibitor, and also by superoxide dismutase (SOD) plus catalase, which catalyzes superoxide into H<sub>2</sub>O via H<sub>2</sub>O<sub>2</sub> (14,19). Interestingly, SB202190 attenuated the activation of ERK kinase, but it remains to be clarified whether p38 MAPK and MEK1 interact with each other and whether the activation of kinases is the consequence of mitochondrial death signaling or vice versa.

### Mitochondria and Cell Signaling Mediate Neuroprotective Function of Propargylamines

Neuroprotection is a new therapeutic strategy to slow or halt the progression of PD and other neurodegenerative disorders (39-42). The apoptotic cascade, which is activated sequentially and progresses rather slowly, is proposed as a target of neuroprotection (3). Recently, a series of propargylamine derivatives, rasagiline (a secondary cyclic benzylamine), (-)-deprenyl (a tertiary aralkylamine),




Fig. 9. Activation of caspase-3 by SIN-1 and suppression by a p38 inhibitor, SB202190. (A) The cells were treated with SIN-1, and caspase-3 activity in the cell lysate was measured with Asp-Glu-Val-As-4-methylcumaryl-7-amide as a substrate. (B) the cells were treated with 40  $\mu$ M SB202190 and then 10  $\mu$ M SIN-1 for 18 h; then, the activities of caspase-3 were determined. \* $p < 0.01$  compared to the control.

and 2-HMP [*N*-(2-hexyl)-*N*-methyl-propargylamine, a tertiary branched alkylamine], have been proved to protect neurons from cell death induced by ROS-RNS, neurotoxins, and other stimuli (41–47). At present, rasagiline is the most potent in preventing apoptosis. The hitherto-confirmed mechanism underlying the neuroprotection by propargylamines is shown in Fig. 10. Rasagiline prevents the decline in  $\Delta\Psi_m$  and swelling of mitochondria (Figs. 8 and 10), the release of cytochrome-*c*, nuclear GAPDH translocation, and fragmentation of nuclear DNA. The antiapoptotic function of rasagiline has been proved to be the result of (1) the stabilization of  $\Delta\Psi_m$  and suppression of mPT (47,48) and (2) the induction of antiapoptotic, prosurvival genes of Bcl-2 (48,49), glial cell line-derived neurotrophic factor (GDNF) (50), and antioxidative enzymes, catalase and SOD (51). The activation of the nuclear factor- $\kappa$ B (NF- $\kappa$ B) pathway has been confirmed to mediate the induction of antiapoptotic genes (50). Rasagiline induced the phosphorylation of the inhibitory subunit (I $\kappa$ B) of NF- $\kappa$ B, and the active p65 subunit was translocated into

nuclei (Fig. 11A). In addition, an inhibitor of I $\kappa$ B kinase, sulfasalazine, suppressed the activation of NF- $\kappa$ B and also the induction of GDNF (50) and *bcl-2* by rasagiline (Fig. 11B). NF- $\kappa$ B is one of the most important transcription factors and is activated by various pathogenic stimuli, including oxidative stress, ischemic insults, and  $\beta$ -amyloid. The induction of antiapoptotic genes depends on the stereochemical structure of rasagiline, suggesting that the binding site in mitochondria might mediate signaling for antiapoptotic gene expression. In addition, we found that ERK kinase was also activated by rasagiline, as an upper stream signal of NF- $\kappa$ B activation. It is interesting that ERK is involved in either proapoptotic signaling through p38 kinase and also in the antiapoptotic pathway through NF- $\kappa$ B. The regulation of these opposite signals should be elucidated to find new drugs suppressing apoptotic cascade and protecting neurons. The stress signaling from mitochondria to nuclei also remains to be elucidated, but the activation of the NF- $\kappa$ B pathway might play a key role, as reported recently (52).




Fig. 10. Mechanisms behind neuroprotective function of propargylamines. Rasagiline prevents opening of the mitochondrial permeability transition (mPT) pore (PTP) and suppresses the mitochondrial swelling, as shown by the light scattering of isolated mitochondria. Rasagiline activates ERK and the NF-κB pathway and induces antiapoptotic Bcl-2, GDNF, and antioxidant enzymes. *bcl-2* mRNA was increased by rasagiline in a dose-dependent way.




Fig. 11. Activation of NF-κB and induction of antiapoptotic *bcl-2* mRNA by rasagiline. (A) Translocation of activated NF-κB in nuclei. SH-SY5Y cells were treated with rasagiline, and in the nuclear fraction, active p65 NF-κB increased with 1 μM and 100 nM rasagiline in a time-dependent way. (B) Sulfasalazine, an inhibitor of IκB kinase suppressed rasagiline-induced induction of the antiapoptotic *bcl-2* family. After treatment with rasagiline, mRNA was subjected to reverse transcription-polymerase chain reaction analysis for the *bcl-2* family. Sulfasalazine suppressed the increase of *bcl-2*, *bcl-xL*, and *mcl-1* by rasagiline. Proapoptotic *bax* was not affected by rasagiline.

## Conclusion

The results of this article suggest that mitochondrial dysfunction might induce the degeneration of dopamine neurons through the modification and inactivation of the proteasome system and the subsequent aggregation of oxidized proteins. At present, the precise mechanism behind the induction of cell death requires further investigation, but it might be quite relevant to consider that the inactivation of proteasome might play a critical role in activation of apoptotic signal. In neurodegenerative disorders, the environmental and genetic factors might induce a malignant cycle among the mitochondrial dysfunction, increased oxidative stress, and the reduced activity of proteasome in neurons, resulting in the typical pathological features, cell death, and formation of inclusion body. Our recent studies on the ubiquitin-proteasome system in the substantia nigra of human brains further support our hypothesis. In the Parkinsonian brain, the 20S  $\beta$ -subunit precipitated with the specified antibody was modified with acrolein, whereas that from the control was not modified.

Future studies on the mitochondrial signaling, protein oxidation, and proteasome system will give arise a new insight in the involvement of oxidative stress in neuronal cell death. The results will provide us with further development of neuroprotective agents for neurodegenerative disorders.

## Acknowledgments

This work was supported by Grant-in-Aid for Scientific Research on Priority Areas (C) from Japan Society for the Promotion of Science (W. M.) and Grant for Dementia and Bone Fracture (W. M., and M. N.) from the Ministry of Health, Labor and Welfare, Japan.

## References

- Halliwell B. (1992) Reactive oxygen species and the central nervous system. *J. Neurochem.* **59**, 1619–1623.
- Kroemer G., Dallaporta B., and Resch-Rigon M. (1998) The mitochondrial death/life regulator in apoptosis and necrosis. *Annu. Rev. Physiol.* **60**, 619–642.
- Thompson C.G. (1995) Apoptosis in the pathogenesis and treatment of disease. *Science* **267**, 1456–1462.
- Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., and Mizuno Y. (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. *Proc. Natl. Acad. Sci. USA* **93**, 2696–29701.
- Sayre L.M., Zelasko D.A., Harris P.L.R., Perry G., Salomon R.G., and Smith M.A. (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation and products are increased in Alzheimer's disease. *J. Neurochem.* **68**, 2092–2097.
- Pedersen W.A., Fu W., Keller J.N., et al. (1998) Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. *Ann. Neurol.* **44**, 819–824.
- Beckman J.S. (1996) Oxidative damage and tyrosine nitration from peroxynitrite. *Chem. Res. Toxicol.* **9**, 836–844.
- Halliwell B. (1997) What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? *FEBS Lett.* **411**, 157–160.
- White R., Brock T., Cjang L., et al. (1994) Superoxide and peroxynitrite in atherosclerosis. *Proc. Natl. Acad. Sci. USA* **91**, 1044–1048.
- Koppal T., Draake J., Yatin S., et al. (1999) Peroxynitrite-induced alteration in synaptosomal membrane proteins: insight into oxidative stress in Alzheimer's disease. *J. Neurochem.* **72**, 310–317.
- Good P.F., Hsu A., Werner P., Perl D.P., and Olanow C.W. (1998) Protein nitration in Parkinson's disease. *J. Neuropathol. Exp. Neurol.* **57**, 338–342.
- Kato Y., Maruyama W., Naoi M., Hashizume Y., and Osawa T. (1998) Immunohistochemical detection of dityrosine in lipofuscin pigments in the aged human brain. *FEBS Lett.* **439**, 231–234.
- Chung K.K.K., Dawson V.L., and Dawson T.M. (2001) The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. *TINS* **24**, S7–S14.
- Maruyama W., Kato Y., Yamamoto T., Oh-hashikawa K., Hashizume Y., and Naoi M. (2001) Peroxynitrite induced neuronal cell death in aging and age-associated disorders. *J. Am. Aging Assoc.* **24**, 11–18.

AU:  
Ref. 1:  
Pls check  
page range.

15. Kato K., Ogino Y., Aoki T., Uchida K., Kawakishi S., and Osawa T. (1997) Phenolic anti-oxidants prevent peroxynitrite-derived collagen modification in vitro. *J. Agric. Food Chem.* **45**, 3004–3009.
16. Tanaka M., Miyabayashi S., Nishikimi M., et al. (1998) Extensive defects of mitochondrial electron-transfer chain in muscular cytochrome *c* oxidase deficiency. *Pediatr. Res.* **24**, 447–454.
17. Mizuno Y., Ohta S., Tanaka M., et al. (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. *Biochem. Biophys. Res. Commun.* **163**, 1450–1455.
18. Maruyama W., Takahashi T., and Naoi M. (1998) (-)Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. *J. Neurochem.* **70**, 2510–2515.
19. Oh-hashi K., Maruyama W., Yi H., Takahashi T., Naoi M., and Isohe M. (1999) Mitogen-activated protein kinase pathway mediates peroxynitrite-induced apoptosis in human dopaminergic neuroblastoma SH-SY5Y cells. *Biochem. Biophys. Res. Commun.* **263**, 504–509.
20. Yamamoto T., Maruyama W., Kato Y., et al. (2002) Selective nitration of mitochondrial complex I by peroxynitrite: involvement in mitochondrial dysfunction and cell death of dopaminergic SH-SY5Y cells. *J. Neural Transm.* **109**, 1–13.
21. Sharpe M.A. and Cooper C.E. (1998) Interaction of peroxynitrite with mitochondrial cytochrome oxidase. *J. Biol. Chem.* **273**, 30,961–30,970.
22. Iwatsubo T., Yamaguchi H., Fujikura M., et al. (1996) Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. *Am. J. Pathol.* **148**, 1517–1529.
23. Ii K., Ito H., Tanaka K., and Hirano A. (1997) Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative disease and the elderly. *J. Neuropathol. Exp. Neurol.* **56**, 125–131.
24. Spillantini M.G., Schmidt M.L., Lee V.M.-Y., Trojanowski J.Q., Jakes R., and Goedert M. (1997)  $\alpha$ -Synuclein in Lewy bodies. *Nature* **388**, 837–840.
25. Choi P., Osrerova-Golts N., Sparkman D., Cochran E., Lee J.M., and Wolozin B. (2000) Parkin is metabolized by the ubiquitin/proteasome system. *Neuroreport* **11**, 2635–2638.
26. Shimura H., Schlossmacher M.G., Hattori N., et al. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implication for Parkinson's disease. *Science* **293**, 263–269.
27. Tanaka Y., Engelender S., Igarashi S., et al. (2001) Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. *Hum. Mol. Genet.* **10**, 919–926.
28. Shamoto-Nagai M., Maruyama W., Kato Y., et al. (2003) An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. *J. Neurosci. Res.* **74**, 589–597.
29. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. *Nat. Neurosci.* **3**, 1301–1306.
30. Calingoson N.Y., Uchida K., and Gibson G.E. (1999) Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. *J. Neurochem.* **72**, 751–756.
31. McNaught K.S.P. and Jenner P. (2001) Proteasomal function is impaired in substantia nigra in Parkinson's disease. *Neurosci. Lett.* **297**, 191–194.
32. Hough R., Pratt G., and Rechsteiner M. (1987) Purification of two high molecular weight proteasomes from rabbit reticulocyte lysate. *J. Biol. Chem.* **262**, 8303–8313.
33. Okada K., Wangpoengtrakui C., Osawa T., Toyokuni S., Tanaka K., and Uchida K. (1992) 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. *J. Biol. Chem.* **274**, 23,787–23,793.
34. Hortelano S., Alvarez A.M., and Bosca L. (1999) Nitric oxide induces tyrosine nitration and release of cytochrome *c* preceding an increase of mitochondrial transmembrane potential in macrophages. *FASEB J.* **13**, 2311–2317.
35. Cassina A.M., Hondara R., Souza J.M., et al. (2000) Cytochrome *c* nitration by peroxynitrite. *J. Biol. Chem.* **275**, 21,409–21,415.
36. Finucane D.M., Bossy-Wetzel E., Waterhouse N.J., Cotter T.G., and Green D.R. (1999) Bax-induced caspase activation and apoptosis via cytochrome *c* release from mitochondria is inhibited by Bcl-xL. *J. Biol. Chem.* **274**, 2225–2233.
37. Ghatan S., Larner S., Kinoshita Y., et al. (2000) P38 MAP kinase mediates Bax translocation in nitric oxide-induced apoptosis in neurons. *J. Cell Biol.* **150**, 335–347.
38. Cheng A., Chan S.L., Milhavel O., Wang S., and Mattson M.P. (2001) P38 MAP kinase mediates

- nitric oxide-induced apoptosis of neural progenitor cells. *J. Biol. Chem.* **276**, 43,320–43,327.
39. Naoi M. and Maruyama W. (2001) Future of neuroprotection in Parkinson's disease. *Parkin Related Dis.* **8**, 139–145.
  40. Ravina B.M., Fagan S.C., Hart R.G., et al. (2003) Neuroprotective agents for clinical trials in Parkinson's disease. *Neurology* **60**, 1234–1240.
  41. Mandel S., Grünblatt E., Riederer P., Gerlach M., Levites Y., and Youdim M.B.H. (2003) Neuroprotective strategies in Parkinson's disease. *CNS Drugs* **17**, 729–762.
  42. Naoi M. and Maruyama W. (2000) Anti-apoptotic function of (–)-deprenyl, in *Milestones in Monoamine Oxidase Research: Discovery of (–)-Deprenyl*, Magyar K. and Vizi E.S., eds., Medicina Publishing House, Budapest, pp. 171–180.
  43. Maruyama W., Takahashi T., Youdim M., and Naoi M. (2002) The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. *J. Neural Transm.* **109**, 467–481.
  44. Maruyama W., Boulton A.A., Davis B.A., Dostert P., and Naoi M. (2001) Enantio-specific induction of apoptosis by an endogenous neurotoxin, *N*-methyl(*R*)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by *N*-(2-heptyl)-*N*-methylpropargylamine. *J. Neural Transm.* **18**, 11–24.
  45. Naoi M., Maruyama W., Akao Y., and Yi H. (2002) Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, *N*-methyl(*R*)salsolinol, and neuroprotection by propargylamines. *J. Neural Transm.* **102**, 607–621.
  46. Maruyama W., Youdim M.B.H., and Naoi M. (2001) Antiapoptotic properties of rasagiline, *N*-propargylamine-1(*R*)-aminoindan, and its optical (*S*)-isomer, TV1022. *Ann. NY Acad. Sci.* **939**, 320–329.
  47. Maruyama W., Yi H., Takahashi T., et al. (2004) Neuroprotective function of *R*-(–)-1-(benzofuran-2-yl)-2-propargylamine, [*R*-(–)-BRAP], against apoptosis induced by *N*-methyl(*R*)salsolinol, and endogenous dopaminergic neurotoxin, in human dopaminergic neuroblastoma SH-SY5Y cells. *Life Sci.* **75**, 107–117.
  48. Maruyama W., Akao Y., Youdim M.H., Davis B.A., and Naoi M. (2001) Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehydes-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, *N*-methyl(*R*)salsolinol. *J. Neurochem.* **78**, 727–735.
  49. Akao Y., Maruyama W., Shimizu S., et al. (2002) Mitochondrial permeability transition mediates apoptosis induced by *N*-methyl(*R*)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, *N*-propargyl-1(*R*)-aminoindan. *J. Neurochem.* **82**, 913–923.
  50. Akao Y., Maruyama W., Yi H., Shamoto-Nagai M., Youdim M.B.H., and Naoi M. (2002) An anti-Parkinson's disease drug, *N*-propargyl-1(*R*)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. *Neurosci. Lett.* **326**, 105–108.
  51. Maruyama W., Nitta A., Shamoto-Nagai M., et al. (2004) *N*-Propargyl-1(*R*)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF- $\kappa$ B transcription factor. *Neurochem. Int.* **44**, 393–400.
  52. Carrillo M.C., Mimami C., Kitani K., et al. (2000) Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rats. *Life Sci.* **67**, 577–585.
  53. Biswas G., Anandatheerthavarada H.A., Zaidi M., and Avadhani N.G. (2003) Mitochondrial to nucleus stress signaling: a distinctive mechanism of NF $\kappa$ B/Rel activation through calcineurin-mediated inactivation of I $\kappa$ B $\beta$ . *J. Cell Biol.* **161**, 507–519.

---

AU:  
Pls cite ref.  
53 in text.



## NEUROPHARMACOLOGICAL, NEUROPROTECTIVE AND AMYLOID PRECURSOR PROCESSING PROPERTIES OF SELECTIVE MAO-B INHIBITOR ANTIPARKINSONIAN DRUG, RASAGILINE

Moussa B.H. Youdim<sup>1</sup>, Wakako Maruyama<sup>2</sup> and Makato Naoi<sup>3</sup>

<sup>1</sup>Eve Topf and NPF Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Technion-Rappaport Faculty of Medicine, Haifa, Israel; <sup>2</sup>Wakako Maruyama, Department of Basic Gerontology, National Institute for Longevity Sciences, Obu, Aichi, Japan;

<sup>3</sup>Department of Neurosciences, Gifu International Institute of Biotechnology, Kakamigahara, Gifu, Japan

### CONTENTS

Summary .....	
Introduction .....	
Monoamine oxidase inhibitory activity of rasagiline .....	
Mechanism of monoamine oxidase B inhibition by rasagiline .....	
Neuropharmacology of rasagiline .....	
<i>In vivo</i> dopamine release and turnover .....	
Neuroprotective activity of rasagiline .....	
Amyloid precursor protein processing activity of rasagiline .....	
Neurotrophic activity of rasagiline:	
The involvement of GDNF, nerve growth factor and NF- $\kappa$ B .....	
Conclusion .....	
References .....	

### Summary

Rasagiline (*N*-propargyl-1*R*-aminoindan) is a novel, highly potent, irreversible monoamine oxidase (MAO)-B inhibitor designed for use as an antiparkinsonian drug. Unlike selegiline, rasagiline is not derived from amphetamine or metabolized to

neurotoxic 1-methamphetamine derivative, and it does not have sympathomimetic activity. Moreover, at selective MAO-B inhibitory dosage, it does not induce a "cheese reaction." Rasagiline is effective as monotherapy or as an adjunct to L-dopa for patients with early and late Parkinson's disease. Adverse events do not occur with greater frequency in subjects receiving rasagiline than in those on placebo. Its *S*-isomer, TVP1022, is more than a thousand times less potent as an MAO inhibitor. However, both drugs have neuroprotective activities in neuronal cell cultures in response to various neurotoxins, as well as *in vivo* (e.g., in response to

**Correspondence:** Prof. Moussa B.H. Youdim, Eve Topf and NPF Center, Technion-Rappaport Faculty of Medicine, Efron St., P.O. Box 9697, Haifa 31096, Israel. Tel.: 972-4-8295-290; FAX: 972-4-8513-145.  
E-mail: Youdim@tx.technion.ac.il




Fig. 1. The structures of rasagiline, selegiline and their respective metabolites aminoindane and l-methamphetamine.

global ischemia, neurotrauma, head injury, anoxia, etc.), indicating that MAO inhibition is not a prerequisite for neuroprotection. The neuroprotective activity of these drugs has been demonstrated to be associated with the propargylamine moiety, which protects mitochondrial viability and mitochondrial permeability transition pore by activating Bcl-2 and downregulating the Bax family of proteins. Rasagiline and its newly developed cholinesterase inhibitor derivatives process amyloid precursor protein (APP) into the neuroprotective-neurotrophic soluble APP $\alpha$  (sAPP $\alpha$ ) by protein kinase C- and mitogen-activated protein kinase-dependent activation of  $\alpha$ -secretase, and they increase nerve growth factor, GDNF and BDNF expression and proteins. Thus, rasagiline and its derivatives may induce neuroprotection, neuroplasticity and long-term potentiation. Rasagiline has therefore been chosen by the National Institutes of Health (NIH) to study its neuroprotective effects in neurodegenerative diseases. Long-term studies are required to evaluate the drug's disease-modifying prospects in Parkinson's and Alzheimer's diseases. © 2005 Prous Science. All rights reserved.

### Introduction

The knowledge that dopamine is oxidatively deaminated equally well by monoamine oxidase (MAO) types A and B (1), the dominance of MAO-B (80%) as compared to MAO-A in the extrapyramidal regions of human brain (1–3) and the absence of the "cheese reaction" in whole animal and isolated tissue preparations by the selective irre-

versible MAO-B inhibitor selegiline (deprenyl) (4) led us to introduction of this irreversible inhibitor as an adjunct to levodopa therapy for Parkinson's disease (5–7). Selegiline has been a useful antiparkinsonian drug, both in monotherapy (8) and as an adjunct to levodopa therapy. Additionally, it has levodopa-sparing action (6, 9, 10). Selegiline is a propargyl derivative of l-methamphetamine. It irreversibly inhibits MAO-B by binding mole per mole covalently to the N5 position of the isoalloxazine moiety of FAD, the cofactor of MAO-B (11, 12). *In vivo*, selegiline is metabolized to its major metabolites l-amphetamine and l-methamphetamine (13) (Fig. 1). In behavioral (14), pharmacological preparations and *in vivo*, it possesses amphetamine-like and sympathomimetic actions (15, 16), which result in its ability to increase blood pressure and heart rate. Its major metabolite, l-methamphetamine, has neurotoxic action. However, as a consequence of not having similar structural drugs, it has not been possible to evaluate selegiline's antiparkinsonian activity or its mechanism of action.

We have identified and developed the highly potent irreversible selective inhibitor of MAO-B, rasagiline [*N*-propargyl-1*R*(+)-aminoindane; TVP-1012] (Fig. 1) (17–22). Rasagiline has been developed as an antiparkinsonian drug (17, 23–27). It is a propargylamine derivative of aminoindane, and unlike selegiline, it is not metabolized to amphetamine but to aminoindane, which has no amphetamine-like sympathomimetic properties (Fig. 1). Rasagiline is an *R*-isomer of the racemic form of the selective




Fig. 2. Comparative *in vitro* MAO inhibitory activities of rasagiline and selegiline in rat brain mitochondrial preparations. Similar but lower effects were seen with liver MAO inhibition (ref. 22).

MAO-B inhibitor, AGN1135 (20, 21). Similarly to selegiline at its selective MAO-B inhibitory dosage, it does not produce the "cheese reaction" in isolated tissue preparations or *in vivo* in rats and cats (16, 28).

Several controlled phase III studies have demonstrated that rasagiline is effective as a monotherapy drug in early and late Parkinson's disease, and as an adjuvant to L-dopa, it significantly reduces the off effect (26, 27, 29, 30, 31).

#### Monoamine oxidase inhibitory activity of rasagiline

Rasagiline's MAO-A and -B inhibitory activities have been determined *in vitro*, as well as acutely and chronically *in vivo* in various tissues of mice, rats, cats and monkeys, together with the activities of its S-isomer TVP1022 and of the racemic compound AGN-1135, in comparison with the activity of selegiline (l-deprenyl) (Fig. 2). The tissues that were studied for MAO inhibition included brain, liver and small intestine. Rasagiline and its racemic form are highly potent, selective, irreversible inhibitors of MAO *in vitro*, with similar potency to that of selegiline (Fig. 2). However, the S-isomer (TVP-1022) is relatively inactive *in vitro* and *in vivo* in the tissues studied. The *in vitro* IC<sub>50</sub> values for inhibition of rat brain MAO activity by rasagiline are 4.43 ± 0.92 nM (type B) and 412 ± 1.23 nM (type A). The ED<sub>50</sub> values for *ex vivo* inhibition of MAO-B in

the brain and liver by a single dose of rasagiline are 0.1 ± 0.01 and 0.042 ± 0.0045 mg/kg, respectively. These same values for MAO-A inhibition are 8.35 ± 2.2 and 2.42 ± 0.39 mg/kg, respectively. *In vivo* rasagiline is between 10–20 times more potent than selegiline, and it maintains its selective MAO-B inhibition in the liver and brain when administered as chronic (21-day) oral dosage, with ED<sub>50</sub> values of 0.014 ± 0.002 and 0.013 ± 0.001 mg/kg, respectively, for these tissues. The degree of selectivity of rasagiline for inhibition of MAO-B as opposed to MAO-A *in vitro* is similar to that of selegiline, with rasagiline being significantly more potent *in vivo*. In fact, rasagiline produces near complete inhibition of MAO-A and -B at doses of 10 and 0.4 mg/kg, respectively (22). This may explain its greater potency for inhibition of human platelet MAO-B. In addition, a rasagiline dose as low as 0.5–2 mg/day has shown efficacy in parkinsonian subjects (27).

#### Mechanism of monoamine oxidase B inhibition by rasagiline

The inhibitory potencies of rasagiline and its S-isomer have been examined in brain, liver and intestine of rats after acute and chronic oral treatment (22) and compared to that of the selective irreversible MAO-B inhibitor, selegiline (4). The results demonstrated a high degree of stereo selectivity

for MAO inhibition by rasagiline and its *S*-isomer. This is reflected in the fact that TVP1022 (the *S*-isomer of rasagiline) is three orders of magnitude less potent as a MAO inhibitor *in vitro*. In contrast, selegiline and its isomer show only a small degree of stereo selectivity, and in this case the *S*(-) enantiomer is more potent than the *R*(+) enantiomer, opposite to that of rasagiline. The full explanation for this markedly different degree of stereo selectivity between closely allied chemical compounds has become apparent with three-dimensional modeling of the MAO active site. Indeed, the recent crystallographic studies with MAO-B, rasagiline and TVP1022 by Binda *et al.* (32) and Edmondson *et al.* (33) have clearly shown that while rasagiline enters the MAO-B active site gorge and binds to it irreversibly, TVP1022 makes a 180-degree turn to enter the gorge (unpublished data) and slowly but eventually inhibits the enzyme.

Rasagiline, similar to selegiline, is a propargyl-containing drug. However, the propargyl component in rasagiline, unlike that of selegiline, is bound to an aminoindan moiety. The propargyl-containing MAO inhibitors such as clorgyline, pargyline and selegiline are known as suicide inhibitors since they are substrates of the enzyme (11, 34, 35). They inactivate MAO-A and -B selectively and irreversibly by time- and concentration-dependent mechanisms by interacting covalently with the cysteinyl-FAD cofactor of the enzymes at their active centers (36, 37). This interaction takes place between the propargyl group and the N5 of the FAD isoalloxazine component of liver (11) and brain MAO (38). It has been shown for these inhibitors that one mole of the inhibitor inactivates one mole of the enzyme (34), and since rasagiline has the same enzyme-inactivating moiety as those of the aforementioned propargylamines, its mechanism of MAO inactivation is considered to be identical to that of these inhibitors. The 1:1 interaction of propargylamine MAO inhibitors with MAO-A and -B has been used to determine the molecular turnover of these enzymes in the estrus cycle and their response to sex steroids (39), as well as their regulation with steroids (40, 41). The estrus cycle has a profound effect on MAO-A activity, with progesterone inducing and estradiol reducing MAO-A enzyme activity. Studies with endothelial and chromaffin cell cultures, which contain, respectively, MAO-A and -B only, have shown that these steroids affect only synthesis of active MAO-A and its turnover, and not those of MAO-B (41). No adequate explanation has been

put forward as to why steroids do not alter MAO-B expression, what regulates this enzyme, what its function is in the brain and whether this enzyme has other endogenous substrates, such as *N*-acetyl derivatives of diamine oxidase substrates (*e.g.*, spermine, spermidine, putrescine) (42), besides dopamine and phenylethylamine.

A comparison of turnover of rat striatal MAO-B inhibition by rasagiline and selegiline shows remarkable similarities between the two compounds (43). Striatal MAO-B has a significantly slower turnover as compared to MAO-A. It is apparent that rasagiline is a very potent selective MAO-B inhibitor and has a good uptake across the blood-brain barrier, as shown by the similarity of inhibition curves between liver and brain (44). Although when compared *in vitro*, rasagiline had similar potency to selegiline for inhibition of MAO-B, the *in vivo* study showed a greater potency for rasagiline. This greater potency of rasagiline is even more marked if, instead of 50% enzyme inhibition, the dose required for 80% inhibition is measured. The reason for this is not currently known, but it may be due to different rates of metabolism of the parent compounds *in vivo* or to improved tissue penetration of rasagiline. Studies in humans show an approximately 5- to 10-fold greater potency for rasagiline over selegiline for inhibition of platelet MAO-B (unpublished data). Although rasagiline has a greater potency than selegiline, its selectivity for MAO-A and -B inhibition is very similar to what has been reported for selegiline.

The results from studies on rat tissues complement findings in nonhuman primate (monkey) brains (45), where rasagiline was given chronically for 7 days at various doses and MAO-A and -B activities were measured in several brain regions, including caudate nucleus, globus pallidus, cerebral cortex and hippocampus. Rasagiline was shown to be a potent selective inhibitor of MAO-B in the caudate nucleus and globus pallidus, where the activity of MAO-B, similarly to in the human brain, is 4-fold higher than that of MAO-A (45). In human volunteers and parkinsonian subjects, a 0.5, 1.0 or 2.0 mg daily dosage given chronically is sufficient to completely inhibit platelet MAO, which is solely type B. This potency will most likely be reflected in the human brain, since Riederer and Youdim (46) showed that a 10 mg daily dose of selegiline given to parkinsonian subjects fully inhibited platelet MAO-B with a similar inhibitory potency in caudate nucleus, substantia nigra, globus pallidus and thalamus,

in contrast to a limited MAO-A inhibition in these brain regions, as determined at autopsy from subjects on chronic selegiline. Unlike the studies in rat brain, where MAO-A or -B inhibitors do not affect dopamine levels (47), in human brain there was a significant, but moderate, increase (45%) in dopamine levels (enriched by MAO-B), as well as a highly significant increase (3,000%) in the MAO-B substrate phenylethylamine in these regions (48). In contrast, the limited MAO-A inhibition was observed in these regions, and there were no appreciable effects on serotonin or noradrenaline and their metabolites in these regions. Thus, selective inhibition of brain MAO-B can be maintained with the right dosages of selegiline, and it would not be expected to be different for rasagiline, as discussed above regarding studies on rat brain *in vivo* (22).

MAO-A and -B activity recovery after *in vivo* inhibition by rasagiline, which is related to the synthesis of enzyme apoprotein, differs significantly between tissues such as liver, small intestine and brain. The small intestine MAO-B activity has the fastest recovery, while the brain MAO-B activity shows the slowest recovery. In comparison, MAO-A activity recovery in rat brain is significantly faster and the half-life is 3–5 days. These differences in rat brain enzyme activity recovery after rasagiline treatment are not unusual: similar findings have been reported for enzyme recovery after inhibition by selegiline and clorgyline (49, 50). Indeed, a recent comparative study of rasagiline and selegiline showed almost identical results, with a half-life in the striatum of 7–9 days. However, the half-life for recovery of MAO-B after selegiline treatment has been reported to be well over 30 days (40) in primate (monkey and human) brains and 13 days in the rat brain (49, 50).

#### Neuropharmacology of rasagiline

The effects of rasagiline on CNS monoamine levels, behavioral response to fluoxetine, reserpine reversal and cardiovascular responses to tyramine have been studied in a range of doses in rats (51). Rasagiline reverses reserpine-induced ptosis at doses above 2 mg/kg, which are nonselective for MAO-B, but not at MAO-B-selective doses. Combination of rasagiline, at doses up to 20 mg/kg, which is well above its selectivity for MAO-B, with fluoxetine (10 mg/kg) does not induce the behavioral serotonergic syndrome seen following nonselective MAO-A + -B inhibition by tricyclics, and unlike the latter inhibitor, it does not induce behavioral serotonergic nor dopaminergic syndrome in

response to l-tryptophan or L-dopa, respectively (51). Similarly to selegiline (14, 47), when administered orally it does not alter hippocampal or striatal levels of noradrenaline, 5-hydroxytryptamine (5-HT) or dopamine after single or chronic doses of rasagiline up to 2 mg/kg. At doses higher than this, it causes an increase in hippocampal 5-HT and a reduction in 5-hydroxyindole acetic acid (5-HIAA). Striatal levels of dihydroxyphenylacetic acid (DOPAC) are reduced at doses above 1 mg/kg, suggesting inhibition of both MAO-A and -B. However, with chronic oral administration of doses up to 1 mg/kg daily for 21 days, levels of noradrenaline, 5-HT and dopamine in hippocampus and striatum, respectively, are unaffected, but 5-HT increases at 2 mg/kg and striatal dopamine content increases at 2 and 5 mg/kg. It is most likely that at these doses MAO-A is also inhibited, leading to the increase in these neurotransmitters, which are metabolized by MAO-A (14, 47). Rasagiline, similarly to selegiline and reversible MAO-B inhibitors (*e.g.*, lazabemide and milacemide), does not potentiate pressor responses to oral tyramine when administered as single oral doses of up to 5 mg/kg. However, doses of 10 mg/kg do significantly potentiate this response. At this dose, both MAO-A and -B are inhibited, and it is the irreversible inhibition of MAO-A that induces the cheese reaction (16, 52). Similarly, pressor responses to tyramine (5, 10 and 20 mg/kg) are not significantly potentiated following 21-day chronic treatment with rasagiline up to 2 mg/kg daily. Thus, rasagiline does not modify CNS monoamine tissue levels or pressor responsiveness to tyramine at doses selective for inhibition of MAO-B. The greater potency of rasagiline in comparison to selegiline is also reflected in humans, since a 1–2 mg daily dose of rasagiline inhibits platelet MAO-B. Parkinsonian subjects respond to rasagiline doses as low as 0.5–2 mg daily administered as controlled monotherapy and as an adjunct to L-dopa therapy in early and late Parkinson's disease studies (26, 27, 53). This value is significantly lower than the 10 mg daily dosage employed with selegiline. These results, together with the lack of tyramine sympathomimetic potentiation by rasagiline at selective MAO-B inhibitory dosage, indicate that this inhibitor may be a more efficient drug than selegiline in the treatment of Parkinson's disease as either symptomatic or levodopa adjunct therapy. Furthermore, its lack of amphetamine-like metabolites could confer a therapeutic advantage to rasagiline.

### ***In vivo* dopamine release and turnover**

Acute inhibition of MAO-B with selegiline or rasagiline in rats does not alter striatal dopamine metabolism (47), but both drugs chronically increase *in vitro* and *in vivo* release of dopamine (54). The incremental release of striatal dopamine induced by depolarizing concentrations of K<sup>+</sup> is significantly greater with chronic clorgyline (a MAO-A inhibitor), selegiline and rasagiline treatments, where MAO-A and -B are selectively inhibited (55). Single doses of selegiline and rasagiline have no significant effects on striatal dopamine efflux (56). In these studies, only clorgyline reduced dopamine metabolism, whereas dopamine release was enhanced by both chronic MAO-A and -B inhibitor administration. The possibility that an inhibition of high-affinity dopamine transporter by selegiline and rasagiline may be the resultant effect has also been investigated (57). Striatal levels of dopamine transporter are elevated with acute and chronic selegiline administration, but not with rasagiline, clorgyline, nomifensine or amphetamine. Thus, an increase rather than a decrease in dopamine transporter expression appears to be a special property of selegiline and not of other inhibitors. Selegiline is a derivative of l-amphetamine and its major metabolite is l-methamphetamine. It has been suggested that dopamine release may result from this metabolite. However, since rasagiline is not metabolized to amphetamine and has a similar action on striatal dopamine release, this effect is not dependent on the production of amphetamine. The most likely explanation for this effect is the metabolic inhibition of phenylethylamine, a selective substrate of MAO-B, which is highly elevated in response to selegiline in rat brain (58) and parkinsonian brain obtained at autopsy (48). In contrast, neither dopamine, serotonin or noradrenaline metabolism are altered by rasagiline or selegiline in rat brains (14, 47, 59, 60). Although selegiline has been shown to cause a modest but significant increase in parkinsonian striatal dopamine (46), it also profoundly affects phenylethylamine metabolism, with a more than 3,000% increase in parkinsonian striatum levels obtained at autopsy in patients on l-deprenyl therapy for between 4 weeks and 4 years (48). As a specific substrate of MAO-B (58, 61), phenylethylamine is increased in rat brains treated with selegiline. Phenylethylamine is a highly potent releaser of dopamine, as well as an inhibitor of neuronal uptake and a competitive inhibitor of MAO-B. Indeed, at their selective *in vivo* MAO-B inhibitory doses, both selegiline and rasagiline potentiate the

behavioral response to exogenous treatment with phenylethylamine (43). This response is only observed when MAO-B is inhibited by more than 80% (62, 63). These results may have significant implications for understanding the therapeutic action of rasagiline when administered as monotherapy in early and late Parkinson's disease, or when used as an adjuvant to L-dopa. The continuous release of dopamine after chronic rasagiline and selegiline in rat brain (54), together with the long-term selective inhibition of MAO-B in extrapyramidal regions (*i.e.*, caudate nucleus, substantia nigra, globus pallidus and thalamus) (46), may explain why the initial clinical response to rasagiline monotherapy in parkinsonian subjects continues even 8 weeks after the termination of the drug (29), whose half-life is considered to be greater than 30 days (40). There could also be another explanation, such as adaptive postsynaptic dopamine receptor sensitization, but this has not so far been shown for either selegiline or rasagiline.

### **Neuroprotective activity of rasagiline**

#### *In cell culture and in vivo*

Rasagiline possess neuroprotective activity against cell death, as demonstrated *in vitro* (in neuronal cell cultures) and in several *in vivo* preparations in response to neurotoxins and neurotoxic events and serum and nerve growth factor withdrawal in neuronal cell culture (Tables I and II). Rasagiline is among a handful of agents chosen for further study as potential neuroprotective compounds in clinical neuroprotection trials in Parkinson's disease (64). Clinically as an antiparkinsonian drug (26, 27) and experimentally as a MAO-B inhibitor (22, 51), rasagiline is 10–20 times more potent than other agents studied. Similarly, selegiline and alkyl-propargylamines exhibit neuroprotective activities in several neuronal cell culture models, as well as *in vivo* in response to a number of neurotoxins (65–71). This property is not related to

*Table I: In vivo neuroprotective activity of rasagiline in models of neurodegenerative diseases.*

- 
- MPTP model of Parkinson's disease (73)
  - Global ischemia (74, 75)
  - Neurotrauma model of head injury (76)
  - Amyotrophic lateral sclerosis (77)
  - Eae model of multiple sclerosis?
  - Heart ischemia?
  - 6-Hydroxydopamine? (78)
-

Table II. *In vitro* neuroprotective activity of rasagiline in neuronal cell cultures.

Neurotoxic agents	Cell type	
	PC-12	SHSY-5Y neuroblastoma
Glutamate	+	+
SIN-1	ND	+
<i>N</i> -methyl-( <i>R</i> )-salsolinol	ND	+
6-Hydroxydopamine	ND	+
Serum and nerve growth factor deprivation	+	ND
Glucose and oxygen deprivation	+	ND
Oxidanoic acid+	+	
A $\beta$ -amyloid aggregate	+	+
$\alpha$ -Synuclein-Fe aggregate	+	+
TNF- $\alpha$		

the MAO-B inhibitory activity of either rasagiline and its novel cholinesterase-MAO inhibitor derivatives or selegiline (44, 72, 79–81), since the *S*-optical isomer of rasagiline, TVP1022, which has poor MAO-B inhibitory activity, exhibits similar neuroprotective activity (66, 67, 70, 71, 82). Clinical trials with selegiline (83) failed to establish its neuroprotective activity because its symptomatic effect could not be distinguished from a possible neuroprotective action. One reason why neuroprotection was not observed with selegiline in clinical trials (83) may be a consequence of *l*-methamphetamine generation, which could interfere with selegiline's neuroprotective activity (79, 80, 84–86). Although rasagiline (72) and selegiline have similar structures, selegiline's major metabolites *l*-amphetamine and *l*-methamphetamine are thought to be neurotoxic (84–86). However, rasagiline's metabolite is aminoindan, which has been reported to have neuroprotective activity in its own right (87, 88). Indeed, Abu-Raya *et al.* (85) and Bar Am *et al.* (86) have demonstrated that *l*-methamphetamine interferes with the neuroprotective action of selegiline and rasagiline in oxygen-glucose deprivation-induced cell death in nerve growth factor-differentiated PC-12 cells. These findings were confirmed with PC-12 cell cultures in the absence of serum and nerve growth factor. Furthermore, in these studies aminoindan, the major metabolite of rasagiline, prevented the neurotoxicity of *l*-methamphetamine, the major metabolite of selegiline (86), supporting the results from *in vivo* neuroprotective studies with aminoindan (87, 88) (Fig. 3).

Similarly to selegiline, rasagiline and TVP1022 protect against serum and nerve growth factor withdrawal-induced apoptotic death in partially dif-

ferentiated PC-12 cells (and SHSY-5Y neuroblastoma cells, data not shown). Moreover, their activity appears to be superior to that of selegiline (Fig. 3). The results of these studies are very similar to the neuroprotective actions observed for rasagiline and selegiline in the prevention of PC-12 cell death during oxygen-glucose deprivation. Serum and nerve growth factor withdrawal in partially neuronally differentiated PC-12 cells results in decreased mRNA and protein of Bcl-2 and SOD, while those of Bax increase (22, 89). Rasagiline can substitute for serum and nerve growth factor to restore these proteins, an action that can be prevented with transcriptional and translational inhibitors cycloheximide and actinomycin D (Fig. 3). These findings suggest that rasagiline induces the gene-dependent synthesis and degradation of mitochondrial cell survival proteins. Furthermore, the neuroprotective activity of rasagiline, both *in vitro* in PC-12 and SHSY-5Y cells and *in vivo*, is associated with its induction of antiapoptotic SOD and catalase (90). The *in vivo* induction of Mn-zinc SOD and catalase by rasagiline was mainly associated with substantia nigra and kidney, two dopamine-rich tissues, without a substantial effect in the hippocampus (90). The induction of these enzymes was concentration and time dependent. The potent MAO-B inhibitory activity of rasagiline, which resides in the interaction of its propargylamine moiety with FAD co-factor of the enzyme (22), is unrelated to its neuroprotective activity (44, 66, 67, 70, 71). This view is supported by the observations that its *S*-optical isomer TVP1022 (44, 66, 71) and other derivatives (81), which have more than 1000-fold lower MAO-B inhibitory activities (22), have similar neuropro-




Fig. 3. The prevention of apoptotic death in serum- and nerve growth factor (NGF)-deprived PC-12 cells by rasagiline. The effects of translational and transcriptional blocked by cycloheximide and actinomycin D (ref. 44).

tective activities in cell culture and *in vivo* (44, 66–69, 91). Furthermore, PC-12 cells and human SH-SY5Y neuroblastoma cells contain only MAO-A (92, 93), and the concentration of rasagiline employed in neuroprotective studies would not be sufficient to inhibit this enzyme. It is apparent that the neuroprotective activity of rasagiline and TVP1022 may be superior to that of selegiline, as reported by Abu-Raya *et al.* (85), Maruyama *et al.* (70, 71) and Bar Am *et al.* (86) (Fig. 4). This superior neuroprotective activity may result from the differences between the structure of selegiline and those of rasagiline and its derivatives. Selegiline is a derivative of amphetamine and is metabolized to methamphetamine *in vivo*, and similarly to amphetamine, it is a sympathomimetic compound (15, 25). Methamphetamine is known to be neurotoxic to dopaminergic neurons *in vivo* and to PC-12 and neuroblastoma cells *in vitro* (86, 94). Not only do the studies with l-methamphetamine confirm its neurotoxicity in cell culture, but we have also shown that unlike the aminoindan metabolite of rasagiline, l-methamphetamine prevents the neuroprotective activity of selegiline as well as that of rasagiline (Fig. 4). However, rasagiline is an aminoindan derivative, and neither it nor aminoindan is vasoactive (51). Unlike methamphetamine, aminoindan has little effect on sympathetic nervous function. Furthermore, both compounds demonstrate neuroprotective activity in

serum- and nerve growth factor-free PC-12 cell cultures. Against l-methamphetamine, the major metabolite of selegiline (81, 86) (Fig. 4), it has been established that the neuroprotective activity of propargylamines such as rasagiline, its derivative and selegiline resides in the propargylamine moiety. Our recent study on the neuroprotective activity of rasagiline in PC-12 cells (86), together with previous observations (70, 71, 81, 85), indicate that rasagiline may have a greater neuroprotective potency. This may be attributed to a combination of the propargylamine moiety and the aminoindan backbone of the drug. Indeed 4-hydroxyaminoindan was reported to be protective in global ischemia in gerbils. Rasagiline prevents the neurotoxicity of glutamate in PC-12 cells (unpublished data) and primary cultures of rat hippocampal neurons (25), as well as in global ischemia in gerbils (87). The metabotropic glutamate 1 (mGlu1) receptor antagonist, 1-aminoindan-1,5-dicarboxylic acid (AIDA), which reduces neuronal death following oxygen-glucose deprivation in murine cortical cells and rat organotypic hippocampal cultures and after *in vivo* global ischemia in gerbils, possesses an aminoindan to which the dicarboxylic moiety is attached at its 1 position (95). The structural similarity in propargylamine attachment to position 1 of aminoindan of rasagiline and its pharmacological neuroprotective activity to AIDA cannot be unno-






Fig. 4. The neuroprotective effect of rasagiline's metabolite aminoindan and the neurotoxicity of selegiline's metabolite methamphetamine in PC-12 cells (ref. 86).

ticed. These results may point to a possible role for rasagiline as an mGlu1 antagonist. Support for this has come from cDNA microarray gene expression and proteomics with chronic rasagiline treatment in mice. Rasagiline significantly decreases the expression as well as the proteins of the glutamate and AMPA receptor in the mid brain of mice (96). Furthermore, rasagiline's metabolite aminoindan, unlike selegiline's metabolite methamphetamine, not only has no toxic effects, but also has neuroprotective activity under the conditions studied. Its generation *in vivo* may have an additive neuroprotective effect to that of rasagiline. As one of a few compounds identified for neuroprotective studies in Parkinson's disease (64), rasagiline may have the added advantage of neuroprotective properties arising from both its nontoxic metabolite and the parent compound. The involvement of the protein kinase C (PKC)-dependent mitogen-activated protein (MAP) kinase pathway in the neuroprotective activity of rasagiline in the absence of serum and nerve growth factor has recently been demonstrated. The ERK inhibitor PD98096 and the PKC inhibitor GF109203X prevent the neuroprotective activity of

rasagiline normally observed in PC-12 cells in the absence of serum and nerve growth factor (86) and will be discussed later.

#### *Mitochondrial permeability transition pore and neuroprotective activity of rasagiline*

Mitochondria are potent integrators and coordinators of cell death and survival. Apoptosis and necrosis are modes of cell death that play an integral part in a variety of biological processes, and their demise has been implicated in variety of neurodegenerative diseases, including Parkinson's, Alzheimer's and Huntington's diseases, as well as in non-neurodegenerative diseases such as cardiovascular disease and diabetes (for reviews, see refs. 97–101). The participation of mitochondrial-induced apoptosis in, for example, neuronal and cardiovascular disease-related cell death has not been fully established and therefore remains a controversial subject. Nevertheless, mitochondrial-induced apoptosis has been a target for study of toxin-induced cell death and neuroprotection in progressive loss of neurons and cytoprotection in cardiovascular diseases with variety of pharmacological agents.




Fig. 5. The mechanism by which various neurotoxins induce neurotoxicity- and apoptosis-induced neuronal death.

The initial phase of apoptosis is triggered in response to an induction phase resulting from a variety of initial insults, including xenobiotics, parkinsonism endogenous (*N*-methyl-(*R*)-salsolinol) and exogenous (6-hydroxydopamine and *N*-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [MPTP]) neurotoxin radiation, oxidative stress, etc. This results in an accompanying change in mitochondrial membrane permeability and a decline in mitochondrial membrane potential ( $\Delta\psi_m$ ), swelling of the mitochondria and opening of the mitochondrial permeability transition pore (MPTp) complex, inhibition of the ubiquitin-proteasome complex, release of mitochondrial cytochrome *c* and activation of caspases, especially caspase 3, resulting in cell death by apoptosis (Fig. 5). Mitochondrial permeability transition pores play a central role in the induction and prevention of apoptosis-induced cell death and consists of mitochondrial multiprotein complex, the exact nature of which is not yet fully known. However, it is known to include porin, hexokinase, peripheral benzodiazepine receptor, creatine kinase and cyclophilin D (Fig. 6).

The direct involvement of mitochondrial permeability transition pores in apoptotic-induced death of mammalian cells, including neurons, in cell culture and *in vivo* has been well documented for a variety of agents. The important role of mitochondrial permeability transition pores is also supported by the findings that the mitochondrial permeability

transition pore complexes, particularly VDAC (voltage-dependent anion channel) and ANT (adenosine nucleotide translocase), are direct functional targets for the Bcl-2 family of proteins (Fig. 6). Mitochondrial phase function is controlled by oncogenes and antioncogenes of the Bcl-2-Bax family. Antiapoptotic members (*e.g.*, Bcl-2, Bcl-XL, etc.) stabilize mitochondrial permeability transition pores, while pro-apoptotic members (*e.g.*, Bax, Bak, Bad and Bid) promote and increase mitochondrial membrane permeability (for reviews, see refs. 97–101). For example, we have shown that in response to the endogenous dopaminergic neurotoxin, *N*-methyl-(*R*)-salsolinol (SIN-1 peroxynitrite donor and 6-hydroxydopamine not shown), in the integration phase, the following responses occur in SHSY-5Y neuroblastoma cell mitochondria: a loss of  $\Delta\psi_m$ , swelling of the mitochondria matrix (Fig. 7) and oxidative stress, and opening of mitochondrial membrane permeability (Fig. 8). Pretreatment of these cells with rasagiline prevents these effects (Fig. 6–8). In addition, there is inhibition of the ubiquitin-proteasome system by the neurotoxin, resulting in release of toxic intermembrane proteins such as cytochrome *c*, which rasagiline inhibits (68, 69). These responses are followed by a complex set of events which include activation of pro-caspases and caspase 3 activation (which rasagiline prevents [66, 67]), resulting in nuclear chromatin condensation, DNA fragmentation and changes in the plasma membrane that culminate in the death of SHSY-5Y




Fig. 6. Sites of rasagiline and TV3326 neuroprotective actions in preventing neurotoxin (sin-1, 6-hydroxydopamine and *N*-methyl-(*R*)-salsolinol) induced opening of mitochondrial permeability transition pore (MPTp) (ref. 53).

cells (Fig. 5). Rasagiline-induced neuroprotection exhibited in response to *N*-methyl-(*R*)-salsolinol is also seen with a number of other neurotoxic events and compounds that induce neuronal death (Table I, Fig. 5). This has provided the first evidence that propargylamines and rasagiline antiapoptotic drugs regulate the anti- and pro-apoptotic signaling pathway in mitochondria. The ability of rasagiline to inhibit *N*-methyl-(*R*)-salsolinol-induced collapse of mitochondrial membrane potential ( $\Delta\psi_m$ ), the swelling of mitochondria (Fig. 7) and mitochondrial membrane permeability opening (Fig. 8) in SHSY-5Y cells is associated with activation of antiapop-

totic Bcl-2 family proteins. Evidence for this has come from the studies demonstrating that rasagiline increases mRNAs and proteins of Bcl-2 and Bcl-Xl, while decreasing those of Bax and Bad in SHSY-5Y and PC-12 cells (submitted for publication). Furthermore, Bcl-2-overexpressed SHSY-5Y cells behave identically to rasagiline-treated cells by being resistant to neurotoxicity with *N*-methyl-(*R*)-salsolinol (SIN-1 and 6-hydroxydopamine not shown) (Figs. 6, 7) (53, 102). The neurotoxicity induced by *N*-methyl-(*R*)-salsolinol in SHSY-5Y cells, resulting in the inhibition of the ubiquitin-proteasome system, is associated with cytosolic translo-




Fig. 7. Prevention of rat liver or brain mitochondrial swelling by rasagiline as induced by neurotoxin *N*-methyl-(*R*)-salsolinol (ref. 102).




Fig. 8. Prevention of the permeability transition by rasagiline in isolated mitochondria as induced by *N*-methyl-(*R*)-salsolinol, but not of that induced by  $Ca^{2+}$  (ref. 102).

cation of pro-apoptotic GAPDH. However, it is not known whether the two are linked or independent pathways leading to apoptosis and cell death. Both rasagiline- and Bcl-2-overexpressed cells prevent these processes (68, 69). Further support for the participation of Bcl-2 family proteins in the neuroprotective activity of rasagiline has come from cDNA microarray gene expression in rat striatum with chronic rasagiline treatment. In these studies, cell survival (Bcl-2, Bcl-xl, AKT, PKC) and death (FAS, Bax and Bad, JNK) are respectively up- and downregulated (96, 103).

Structure-activity relationship studies with propargylamines have indicated that the propargyl moiety is crucial for the neuroprotective activity (75, 104–106), since although the aminoindan metabolite of rasagiline is not antiapoptotic, in certain other circumstances it has neuroprotective activity, as in the case of serum withdrawal in partially neuronally differentiated PC-12 cells (81, 86). The mechanism responsible for the neuroprotective action of rasagiline in some respects resembles that of cyclosporine A and immunophilins, which have been shown to have neuroprotective activity against a variety of neurotoxins, including *N*-methyl-(-*R*)-salsolinol and MPTP (107). However, rasagiline is unable to fully suppress the Ca<sup>2+</sup>-induced mitochondrial membrane permeability opening, as seen with BCL-2 overexpression (Fig. 7) and with the action of bonkrekic A and propargylamine, all of which target respective components of the mitochondrial permeability transition pore complex. Nevertheless, in many respects the neuroprotective response of SHSY-5Y cells to rasagiline is very similar to that of cells with overexpressed Bcl-2 (68, 102, 108). Such cells are also resistant to apoptosis by neurotoxins such as *N*-methyl-(-*R*)-salsolinol, and there is no collapse of  $\Delta\psi_m$ , no inhibition of the ubiquitin-proteasome system, no release of cytochrome *c* and no GAPDH translocation from the cytoplasm to the nucleus in response to the neurotoxin (Fig. 5) (68, 102, 108). Our current studies are directed at identifying the target protein(s) upstream and determining at which VDAC protein site rasagiline acts upon the mitochondria (68, 69). Preliminary proteomic studies suggest that upstream rasagiline acts to downregulate FAS and FAS receptor while upregulating PKC (109).

#### **Amyloid precursor protein processing activity of rasagiline**

*Activation of PKC-dependent MAP kinase pathway*  
PKCs, which are abundant in neuronal tissues (110), are involved in neuronal survival and func-

tions of neuronal trophic factors (111, 112). They are critical in the formation and consolidation of different types of memory (113), suggesting a crucial role for PKC in the aberrant signal transduction occurring in Parkinson's and Alzheimer's disease brain (114). Indeed, several reports document a deficit in PKC isoform levels in Alzheimer's disease (115–117), which might lead to a reduced responsiveness of brain tissues to growth factors and neurotransmitters, including acetylcholine (114, 118). Furthermore, a defect in PKC activation in Alzheimer's disease has been documented as a marked loss of redistribution of cytosolic PKC to the particulate fraction in response to phorbol esters and K<sup>+</sup> depolarization in tissue slices from hippocampus, temporal and frontal cortex (119). *In vitro* studies have established the involvement of PKC and PKC-coupled receptors in the nonamyloidogenic  $\alpha$ -secretase pathway of the amyloid precursor protein (APP) cleavage (120–123). There is also evidence for the regulation of secretory APP processing by PKC-dependent mechanisms under *in vivo* conditions (124–126).

Recently, a series of novel analogues was synthesized with a carbamate cholinesterase inhibitory moiety in the aminoindan structure of rasagiline, with the purpose of preserving its neuroprotective activity and also to inhibit acetylcholinesterase in order to increase cholinergic transmission (127, 128). These analogues were designed for use in the treatment of Alzheimer's disease. The *R*-enantiomer of these compounds, TV3326 ([*N*-propargyl-(3*R*)aminoindan-5-yl]-ethyl methyl carbamate), inhibits cholinesterase and MAO and improves memory impairment in scopolamine-treated rats. Its *S*-isomer, TV-3279, which is also a cholinesterase inhibitor, has no MAO inhibitory activity, but it does have similar action in preventing scopolamine impairment in the spatial learning test (127, 128). These compounds retained the neuroprotective activities of rasagiline in partially differentiated PC-12 cells deprived of serum and nerve growth factor, as well as *in vivo* (44, 81, 127). They also prevented A $\beta$ APP-induced PC-12 cell death (104). In addition, rasagiline, together with its anti-Alzheimer's drug derivatives TV3326 and TV3279, induces the release of the nonamyloidogenic  $\alpha$ -secretase form of soluble APP (sAPP) from SH-SY5Y neuroblastoma and PC-12 cells by mitogen-activated protein kinase (MAPK)- and PKC-dependent mechanisms (104, 129). These processes have been shown to be directly depen-